Workflow
Breast - Cancer Treatment
icon
搜索文档
Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care
WSJ· 2025-12-10 22:20
核心观点 - 与标准内分泌疗法相比 Giredestrant 将疾病复发或死亡风险降低了30% [1] 药物疗效数据 - Giredestrant 在降低疾病复发或死亡风险方面显示出优于标准疗法的疗效 风险降低幅度为30% [1]